Home > Insider Trading > Chemomab Therapeutics Ltd. > Profile

Chemomab Therapeutics Ltd. (CMMB)

Market is closed

Sector: Pharmaceutical Preparations

Related Insiders

Nissim Darvish, Director, 2023-07-05
M. Jill Quigley, Director, 2023-06-20
Sigal Fatal, Chief Financial Officer, 2023-06-16

Nissim Darvish, Director, 2023-07-05
M. Jill Quigley, Director, 2023-06-20
Sigal Fatal, Chief Financial Officer, 2023-06-16
Charles Alan Moses, Director, 2023-03-23
Claude Nicaise, Director, 2023-03-23
Harris Neil Cohen, Director, 2023-03-23
Partnership Limited Gp Biofund Israel Orbimed, Large Shareholder, 2023-01-05
Ltd. Gp Israel Orbimed, Large Shareholder, 2023-01-05
Adi George Mor, Chief Scientific Officer, 2023-01-05
Bejosa Matthew Frankel, Chief Medical Officer, 2022-11-15
Donald Marvin, Executive Vp, Cfo & Coo, 2022-06-21
Michael Joel Maryles, Director, 2022-05-25
R Dale Pfost, Chief Executive Officer, 2022-03-15
P Stephen Squinto, Director, 2021-04-21
Arnon Aharon, Chief Medical Officer, 2021-03-25
Peter Thiel, Large Shareholder, 2021-03-19
Stanislav Polovets, Director, 2021-03-12
Andrew Fine, Chief Financial Officer, 2021-03-11
J. Stephen Dipalma, Chief Financial Officer, 2020-05-07
Ofer Gonen, Director, 2020-01-02
Access Industries, Llc, Other, 2020-01-02
Access Industries Management, Llc, Other, 2020-01-02
Ltd. Industries Biotechnology Clal, Large Shareholder, 2020-01-02
Access Industries Holdings Llc, Large Shareholder, 2020-01-02
Len Blavatnik, Other, 2020-01-02
L Reginald Hardy, Director, 2020-01-02
Ruth Alon, Director, 2020-01-02
Jonathan Burgin, See Remarks, 2020-01-02
T Dennison Veru, Director, 2020-01-02
Frank Haluska, Chief Executive Officer, 2020-01-02
Michal Ohev-Zion Gilon, Vp, Research And Development, 2020-01-02
Salar Roshan, Head Of Business Development, 2020-01-02
T Sean Daly, Vp, Clinical Operations, 2020-01-02
Ron Knickerbocker, See Remarks, 2020-01-02
T. Isaac Kohlberg, Director, 2020-01-02
Efrat Makov, Director, 2020-01-02
David Kerstein, Chief Medical Officer, 2020-01-02
Lawrence Howard, Director, 2020-01-02
Ltd. Management Capital Gabriel, Large Shareholder, 2019-12-31

Show All Insiders (39)

Hedge Fund Popularity

Display

Display Share Price

Display Large Version

Hedge Fund Holdings

Filing Period:

Last updated on February 14, 2024, 4:14 pm based on SEC 13F filings Last update: February 14, 2024, 4:14 pm

No.	Hedge Fund	Shares	Value	% Port
1.	OrbiMed Advisors Samuel Isaly	2,241,274	$1,143,050	0.02%
2.	Ikarian Capital Neil Shahrestani	213,392	$108,829	0.01%
3.	Two Sigma Advisors John Overdeck And David Siegel	35,400	$18,054	0%
4.	Citadel Investment Group Ken Griffin	32,677	$16,665	0%
5.	Millennium Management Israel Englander	19,701	$10,048	0%

Insider Trading: Purchases See All

Insider	Price	Amount	Relationship	Remaining Holdings	Date	Form 4
Marvin	$3.25	250	Officer	2,000	2022-03-16	Filing
Marvin	$3.30	250	Officer	1,750	2022-03-16	Filing
Maryles	$2.76	33	Director	1,433	2022-05-24	Filing
Maryles	$2.89	400	Director	1,400	2022-05-24	Filing
Cohen	$3.19	2,000	Director	12,409	2022-05-18	Filing

Insider Trading: Sales See All

Insider	Price	Amount	Relationship	Remaining Holdings	Date	Form 4
Orbimed	$4.51	70,524	Large Shareholder	2,241,274	2023-01-03	Filing
Orbimed	$3.34	266,376	Large Shareholder	2,311,798	2023-01-03	Filing
Mor	$5.03	6,100	Officer, Director	251,147	2023-01-03	Filing
Mor	$5.03	7,700	Officer, Director	317,075	2023-01-03	Filing
Cohen	$2.00	2,409	Director	10,000	2022-11-16	Filing

Institutional Investors' Holdings

Filing Period:

No.	Name	Shares	Value	% Port
1.	Morgan Stanley	70,915	$36,167	0%
2.	Two Sigma Investments, Lp	56,305	$28,716	0%
3.	Kestra Private Wealth Services, Llc	31,241	$15,933	0%
4.	Xtx Topco Ltd	29,047	$14,814	0%
5.	Boothbay Fund Management, Llc	26,529	$13,530	0%

News See All

Click here to See All News

Chemomab Therapeutics Ltd. (CMMB)

Related Insiders

Hedge Fund Popularity

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Q1 2023 Earnings Call Transcript

5 Worst Stock Picks of Cathie Wood